Foamix Pharmaceuticals Ltd. (FOMX)
(Delayed Data from NSDQ)
$3.25 USD
+0.03 (0.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.25 USD
+0.03 (0.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Foamix (FOMX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foamix (FOMX) delivered earnings and revenue surprises of -20.59% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Foamix (FOMX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Navigating The Healthcare Industry: Science Fiction Turns to Reality
by Panel Of Zacks Experts
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
Foamix Initiates Phase II Study on Acne Combination Foam
by Zacks Equity Research
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foamix (FOMX) delivered earnings and revenue surprises of -16.67% and -67.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foamix (FOMX) delivered earnings and revenue surprises of -22.58% and -21.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Foamix (FOMX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Foamix (FOMX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Foamix (FOMX) stock based on the movements in the options market lately.
Foamix's Acne Candidate Succeeds in Study, Shares Rally
by Zacks Equity Research
Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.
Implied Volatility Surging for Foamix Pharmaceuticals (FOMX) Stock Options
by Zacks Equity Research
Investors in Foamix Pharmaceuticals (FOMX) need to pay close attention to the stock based on moves in the options market lately.
Foamix (FOMX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foamix (FOMX) delivered earnings and revenue surprises of 22.03% and -12.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA
by Zacks Equity Research
Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.
Allergan Acne Candidate Meets Endpoints in Phase III Studies
by Zacks Equity Research
Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline
Foamix Completes Enrolment in Phase III Acne Drug Studies
by Zacks Equity Research
Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies